Michael F. Mahoney, Chairman, President and CEO of Boston Scientific Corp (BSX), disclosed an open-market purchase of 186,240 shares on August 3, 2026, according to a Form 4 filing. The transaction was executed at a price of $48.33 per share, for a total outlay of $9,001,407.55 out of Mahoney’s own funds.
Following the purchase, Mahoney’s directly held stake stands at 1,590,024 shares. The filing lists the transaction as a straightforward open-market buy rather than an option exercise, grant, or other form of equity compensation, meaning Mahoney paid cash at prevailing market prices to increase his personal holding in the company he leads.
Why Insider Buys Draw Attention
Open-market purchases by top executives are watched closely by market observers because they represent a direct financial commitment made with personal capital, as opposed to shares received through routine compensation packages. Academic research on insider trading patterns has found that clusters of open-market buying, particularly by senior executives, can statistically correlate with subsequent periods of relative outperformance, though any individual filing is only one data point and does not guarantee future results.
This filing is being reported as a disclosure of record rather than as guidance on portfolio decisions. The size of the purchase, at roughly $9 million, places it among the more notable executive buys tracked on this site for large-cap healthcare and medical device names, given the scale of capital involved.
Boston Scientific has a broad footprint in cardiovascular, endoscopy, and neuromodulation device markets, and executive transactions of this nature are one of several signals used to gauge insider sentiment alongside institutional ownership data. Readers following how large asset managers position themselves around companies like Boston Scientific may find related context in our coverage of quarterly institutional filings, including RENAISSANCE GROUP LLC: 13F Portfolio Moves Tracked Quarterly, which tracks how one prominent fund has adjusted its holdings over time.
Form 4 filings such as this one are required to be submitted to the SEC within two business days of a reportable transaction, giving the market a relatively current view of executive activity. Mahoney’s post-transaction ownership figure of 1,590,024 shares held directly reflects only his direct holdings as reported in this filing and does not include any indirect holdings that may exist through trusts or other vehicles, which are not detailed here.
As with all insider transaction disclosures, this report reflects information contained in the public SEC filing and is intended for informational tracking purposes.
→ See all BSX coverage on WhoIsBuyingNow
Source: original SEC Form 4 filing.